OncoCyte is a molecular diagnostic company focused on developing and commercializing laboratory-developed tests (LDTs) to serve unmet medical needs across the cancer care continuum. Co. is developing DetermaDx, a non-invasive blood-based test that measures biomarkers of the immune system's response to cancer to help determine whether lung nodules detected through imaging are likely benign. Co.'s first commercially available LDT is DetermaRx, a predictive molecular test for early stage adenocarcinoma of the lung. Co. has expanded its portfolio to include a gene expression-based test that it calls DetermaIO, developed to identify patients most likely to respond to immunotherapy drugs. The OCX stock yearly return is shown above.
The yearly return on the OCX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OCX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|